EFX Stock Recent News

Robust growth across segments drives EFX's top line in the fourth quarter of 2024.

For Equifax, macro headwinds from a job market slowdown and the volatile mortgage market — where uneven loan demand has been a hallmark amid relatively high interest rates — have impacted top-line momentum and forward-looking guidance. As discussed during an earnings call with analysts Thursday (Feb.

The headline numbers for Equifax (EFX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Equifax (EFX) came out with quarterly earnings of $2.12 per share, beating the Zacks Consensus Estimate of $2.10 per share. This compares to earnings of $1.81 per share a year ago.

ATLANTA , Feb. 6, 2025 /PRNewswire/ -- Equifax ® (NYSE: EFX) today announced financial results for the quarter and full year ended December 31, 2024. Fourth quarter 2024 revenue of $1.419 billion up 7%, with 9% local currency revenue growth, despite weaker U.S. hiring and mortgage markets.

ATLANTA , Feb. 5, 2025 /PRNewswire/ -- Equifax ® (NYSE: EFX) today announced that the Equifax Board of Directors declared a quarterly dividend of $0.39 per share, payable on March 14, 2025, to shareholders of record as of the close of business on February 21, 2025. Equifax has paid cash dividends for more than 100 consecutive years.

EFX's fourth-quarter 2024 revenues are expected to have increased due to healthy mortgage activities.

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Equifax (EFX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.

Equifax (EFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Company's stock surged over 100% after positive 96-week results from its phase 2b SYMMETRY study using EFX to treat F4 compensated cirrhosis due to MASH patients. The company achieved a significant reversal of cirrhosis, with 39% of patients showing improvement compared to 15% on placebo, highlighting EFX's efficacy. Upcoming catalysts include phase 3 SYNCHRONY studies targeting F1-F3 and F2-F3 MASH patients, with data expected in the first half of 2026 and 2027, respectively.